GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

aTyr Pharma ATYR · USD

Health Care · US listing · 🇺🇸 United States

Compare

3.69

-9.56%

Close of 19 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

aTyr Pharma — daily ATYR Delayed
Market value
$361.6m
Last close × shares
Volume
80.6k
Shares, 19 Nov 2026

About aTyr Pharma

From its filings with the US Securities and Exchange Commission

SEC filings

aTyr Pharma is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ATYR. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $190,000 and a net loss of $74.1m. At that date it held total assets of $93.0m and shareholders' equity of $67.5m.

In its own words

We are a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. Our discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by our proprietary library of domains derived from all 20 tRNA synthetases.

Our lead therapeutic candidate is efzofitimod, a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ILDs are predominantly immune-mediated disorders that are characterized by chronic inflammation, which can lead to progressive fibrosis of the lung. There are limited treatment options for ILD and there remains a high unmet medical need. Sarcoidosis and systemic sclerosis (SSc, also known as scleroderma)-associated ILD (SSc-ILD) are two major forms of ILD. The U.S.

Quoted from its 10-K, filed 5 Mar 2026. Read the filing on SEC.gov ↗

More about aTyr Pharma →

Latest on aTyr Pharma

Our reporting

Next results

4 Mar 2027

Due on 4 Mar 2027. Analysts expect earnings of -6.01 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is aTyr Pharma's ticker?

aTyr Pharma trades as ATYR on its US listing, under ISIN US0021202025.

What was aTyr Pharma's last closing price?

3.69 on 19 Nov 2026. The figure is in USD and is never converted.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.